Structure Therapeutics' Obesity Pill Achieves 16% Weight Loss in Phase 2 Trial

Structure Therapeutics reported that its experimental daily oral obesity pill led to approximately 16% weight loss after 44 weeks in a Phase 2 trial, showing stronger results than Eli Lilly's orforglipron in a shorter period. This positions Structure as a potential competitor in the growing oral GLP-1 obesity treatment market, currently led by injectable drugs from Eli Lilly and Novo Nordisk. The next step is advancing to Phase 3 trials and securing regulatory approval to challenge established market leaders.